Natural killer extracellular vesicles, or NKEVs, are biologic particles derived from natural killer cells and being developed by Vanquish Biologics as a therapeutic platform for difficult cancers.

NKEVs are natural killer cell-derived extracellular vesicles, a biologic therapeutic approach being developed by Vanquish Biologics for cancer treatment. In Vanquish’s platform, these vesicles are produced from natural killer cell sources, prepared as a formulated product, and intended for infusion-based administration in oncology care settings.

Vanquish’s NKEV approach is to develop NKEV therapy as ready-to-formulate, infusion-based product rather than a patient-specific or highly specialized cell therapy workflow. Company materials position NKEVs as potentially more accessible to standard oncology practices and infusion centers because they are designed for powder shipment, on-site formulation, and administration without the same infrastructure burden described for therapies such as CAR-T or transplant-based cell therapy.

Vanquish’s current oncology focus includes glioblastoma multiforme, pancreatic cancer, multiple myeloma, triple-negative breast cancer, and other difficult refractory cancers. Across the company’s recent materials, pancreatic cancer and GBM are emphasized as lead strategic priorities, while multiple myeloma, TNBC, and refractory hematologic cancers remain important parts of the broader pipeline story.

The program is in the preclinical development stage, with repeat-dose toxicity work completed, foundational GLP bioanalytical method validation, and planning underway for stability work, GMP scale-up, GLP IND-enabling studies, pre-IND interaction with FDA, and eventual IND filing. Recent company materials also report a 20x safety margin for the lead candidate in preclinical work conducted.

Partners can contact Vanquish Biologics through our contact form (link), or by calling us at 205-778-0182. Our address is Station 41, 200 9th Ave S., Birmingham, AL 35205. We encourage communication for business development, scientific collaboration, manufacturing partnerships, and investor inquiries.

Unlike individualized cell therapies, Vanquish’s NKEV platform is being developed as an off-the-shelf infusion product designed for conventional oncology delivery settings. The platform is intended to support simpler handling, broader site accessibility, and scalable manufacturing compared with more infrastructure-intensive cell therapy approaches.

Vanquish is currently prioritizing hard-to-treat cancers including pancreatic cancer, glioblastoma multiforme, multiple myeloma, triple-negative breast cancer, and other refractory malignancies.

Vanquish is advancing through preclinical development, with toxicity studies completed and next steps focused on stability, GMP transition, GLP IND-enabling studies, FDA pre-IND planning, and clinical readiness.

For partnership, scientific, or investor inquiries, contact Vanquish Biologics at info@vanquishbiologics.com or 205-778-0182.